Important note

This AI stock analysis for Baxter International is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Baxter International - AI Stock Analysis

Analysis generated May 21, 2024

Baxter International Inc. is a global healthcare company primarily known for its advancements in medical devices, pharmaceuticals, and biotechnology. Founded in 1931, Baxter has a long history of innovation in addressing critical healthcare needs. Its products and services are used in hospitals, clinics, and by patients worldwide. Baxter focuses on three main business segments: Renal Care, Medication Delivery, and Pharmaceuticals. The company has a strong commitment to research and development, which is reflected in its widespread operations and extensive product portfolio.

Fundamental Analysis

Revenue: Baxter International reported a revenue of $3.65 billion for the last quarter. This represents a decrease of 6.13% compared to the previous quarter, indicative of potential short-term challenges. However, compared to the same quarter last year, revenue is up by 0.03%, showing marginal year-over-year growth.

Net Income: Net income for the last quarter stood at $37 million, marking a significant decrease of 84.90% compared to the previous quarter, which raises significant concern. Compared to the same quarter last year, there is a decline of 15.91%, which may indicate ongoing profitability issues.

EBITDA: For the last quarter, Baxter's EBITDA was $383 million, a drastic decrease of 70.87% from the previous quarter. However, compared to the same quarter last year, there was an increase of 6.98%, suggesting some year-over-year improvement despite short-term issues.

P/E Ratio: The current Price-to-Earnings (P/E) ratio is 85.61, which is significantly high. This may indicate that the stock is overvalued, potentially presenting a bearish outlook. High P/E ratios can deter value investors who seek stocks with lower multiples.

Technical Analysis

Stock Price: As of today, Baxter International's stock price is $35.02. This represents a decrease of 11.27% compared to a month ago and a decrease of 15.31% compared to a year ago, signifying potential long-term concerns.

Trend: The stock's recent trend is bearish. The current Simple Moving Average over 10 days (SMA10) is 35.28, which is lower than the previous SMA10 of 35.34, indicating further potential downward price movement.

RSI: The Relative Strength Index (RSI) is sitting at 41.9, indicating neutral conditions. RSI between 30 and 70 is generally considered neutral, and levels below 30 may signal that a stock is undervalued.

Alternative Data Analysis

Job Postings and Employee Sentiment: Baxter International currently has 1,150 open positions, with this number being stable over the last few months. This stability suggests that the company is maintaining a consistent workforce. Employee sentiment is neutral, pointing towards a steady work environment.

Customer Acquisition: The company has approximately 640,000 visitors to their webpage, which is a decrease of 13% over the last couple of months. This downward trend in web traffic could signal a potential decline in customer interest or acquisition.

Customer Engagement: Baxter International has 340 followers on Instagram and 16,000 followers on Twitter, with no meaningful changes in these numbers in the last few months. Stagnant social media engagement may imply challenges in outreach and brand consolidation among consumers.

AI Score: According to AltIndex’s AI score, Baxter International has a score of 50, indicating a "hold" signal. The AI score aggregates fundamental, technical, and alternative data to provide a balanced sentiment analysis.

Conclusion and Recommendation

In conclusion, while Baxter International has a broad and established footprint in the healthcare industry, it is currently facing certain financial and operational challenges. The recent decrease in revenue, net income, and EBITDA highlights immediate concerns. The high P/E ratio suggests that the stock may be overvalued.

The technical analysis indicates a bearish trend with declining prices and neutral RSI, suggesting further potential downside risks. The alternative data sets, including static job postings, declining web traffic, and flat social media engagement, further underline concerns about the company's current market position.

Based on the combined data and the AI score of 50, it is prudent to adopt a "hold" recommendation for Baxter International. Investors should monitor the company's performance closely, particularly for any signs of improvement in revenue growth, profitability, and market engagement, before making further investment decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.